2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEFG165-mediated mammalian angiogenesis

International Journal of Experimental Pathology

Volumn 81, Issue 3, 2000, Pages 191-198

  Norrby, Klas ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; Heparin; Heparin fragments; Low molecular weight heparin; Microvessel network; Microvessel sprouts; Quantification; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; HEPARIN FRAGMENT; LOW MOLECULAR WEIGHT HEPARIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ARTICLE; CANCER; CONTROLLED STUDY; DRUG PROTEIN BINDING; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOEMBOLISM; THROMBOSIS; TUMOR GROWTH; WEIGHT GAIN;

EID: 0033915671     PISSN: 09599673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2613.2000.00150.x     Document Type: Article

References (30)

1. CARMELIET P. & COLLEN D. (1999) Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr. Topics Microbiol. Immunol. 237, 133-158.
2. DERBYSHIRE E.J., YANG Y.C., LI S., COMIN G.A., BELLOIR J. & THORPE P.E. (1997) Heparin-steroid conjugates lacking glucocorticoid or mineralocorticoid activities inhibit the proliferation of vascular endothelial cells. Biochim. Biophys. Acta 1310, 86-96.
3. ECCLES S. (1999) Heparanase: Breaking down barriers in tumors. Nature Med. 5, 735-736.
4. FAITHBROTHER W.J., CHAPE M.A., CHRISTINGER H.W., KEYT B.A. & STAROVASNIK M.A. (1998) Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 6, 637-648.
5. FERRARA N. (1999) Vascular endothelial growth factor: Molecular and biological aspects. Curr. Topics Microbiol. Immunol. 237, 1-30.
6. FOLKMAN J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27-31.
7. FOLKMAN J. & SHING Y. (1992) Control of angiogenesis by heparin and other sulfated polysaccharides. Adv. Exp. Med. Biol. 313, 355-364.
8. FRANCIS J.L., BIGGERSTAFF J. & AMIRKHOSRAVI A. (1998) Hemostasis and malignancy. Semin. Thromb. Hemost. 24, 93-109.
9. 165 using several concurrent mechanisms. J. Biol. Chem. 270, 15059-15065.
10. GREEN D., HULL R.D., BRANT R. & PINEO G.F. (1992) Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339, 1476.
11. HITRAYA E.G., TAN E.M.L., RUDNICKA L. & JIMENEZ S.A. (1995) Expression of extracellular matrix genes in adult human dermal microvascular endothelial cells and their regulation by heparin and endothelial cell mitogens. Lab. Invest. 73, 393-402.
12. HOHENESTER E., SASAKI T., OLSEN B.R. & TIMPL R. (1998) Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J. 17, 1656-1664.
13. HULETT M.D., FREEMAN C., HAMDORF B.J., BAKER R.T., HARRIS M.J. & PARISH C.P. (1999) Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nature Med. 5, 803-809.
14. HULL R.D., RASKOB G.E., PINEO G.F. ET AL. (1992) Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 326, 975-982.
15. KRISTENSEN H.K., TROMBERG E.M., NIELSEN J.R., NIELSEN J.I., JOHANSEN K.B. & ØSTERGAARD P.B. (1991) Development and validation of a size exclusion chromatography method for the determination of molecular masses and molecular mass distribution in low molecular weight heparin. Thromb. Res. 64, 131-141.
16. NASLUND I. & NORRBY K. (2000) NO and de novo mammalian angiogenesis: Further evidence that NO inhibits bFGF-induced angiogenesis while not influencing VEGF165-induced angiogenesis. APMIS 108, 29-37.
17. NORRBY K. (1993) Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis 23 (Suppl. 1), 141-149.
18. NORRBY K. (1996) Vascular endothelial growth factor and de novo mammalian angiogenesis. Microvasc. Res. 51, 154-163.
19. NORRBY K. (1997) Angiogenesis: New aspects relating to its initiation and control. APMIS 105, 417-437.
20. NORRBY K. (1998) Microvascular density in terms of number and length of microvessel segments per unit tissue Volume in mammalian angiogenesis. Microvasc. Res. 55, 43-53.
21. NORRBY K. & ØSTERGAARD P. (1996) Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int. J. Microcirc. 16, 8-15.
22. 165-mediated angiogenesis. Int. J. Microcirc. 17, 314-321.
23. SAKAMOTO N. & TANAKA N.G. (1988) Mechanism of the synergistic effect of heparin and cortisone against angiogenesis and tumor growth. Cancer J. 2, 9-13.
24. SHWORAK N.W. & ROSENBERG R.D. (1999) Heparan sulfate proteoglycans. In Angiogenesis and Cardiovascular Disease. Eds J.A. Ware & M. Simons. Oxford: Oxford University Press. pp. 60-78.
25. 165 to its receptors. Biochem. Biophys. Res. Commun. 203, 1339-1347.
26. SWEENEY S.M., GUY C.A., FIELDS G.B. & ANTONIO J.D. (1998) Defining the domains of type I collagen involved in heparin-binding and endothelial tube formation. Proc. Natl. Acad. Sci. 95, 7275-7280.
27. THORPE P.E., DERBYSHIRE E.J., ANDRADE S.P. ET AL. (1993) Heparin-steroid conjugates: New angiogenesis inhibitors with antitumor activity in mice. Cancer Res. 53, 3000-3007.
28. TYAGI S.C., KUMAR S. & KATWA L. (1997) Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. J. Mol. Cell. Cardiol. 29, 391-404.
29. VLODAVSKY I. & CHRISTOFORI G. (1999b) Fibroblast growth factors in tumor progression and angiogenesis. In Antiangiogenic Agents in Cancer Therapy. Ed. B.A. TEICHER. Totowa, NJ: Humana Press Inc. pp. 93-118.
30. VLODAVSKY I., FRIEDMAN Y., ELKIN M. ET AL. (1999a) Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nature Med. 5, 793-802.